Cocrystal Pharma, Inc. (COCP)

Current Report Filed: 2026-04-30

Key Insights

• Cocrystal Pharma presented clinical data on CDI-988, its first oral protease inhibitor, at a major international antiviral research conference, indicating advancement of a potentially significant pipeline asset.
• The presentation at ICAR 2026 in Prague featured both mechanism of action and clinical advancement details, suggesting the compound has progressed beyond early-stage development and may be approaching later clinical phases.
• This is a Regulation FD disclosure with no material financial impact disclosed, representing routine investor relations activity rather than a material business event.
• The filing was signed by James Martin as Co-Chief Executive Officer and Chief Financial Officer, indicating dual leadership structure at the company.

Sentiment: Positive Significance: 4/10

View Original Filing →

Annual Report Filed: 2026-03-31

Key Insights

• The company's research and development expenses have increased year-over-year, indicating continued investment in its drug pipeline.
• Cocrystal Pharma has raised additional capital through an at-the-market offering and a securities purchase agreement, bolstering its financial position.
• The company has made progress in its clinical trials, with a Phase 1B trial for one of its drug candidates ongoing and plans for a Phase 2A trial.

Sentiment: Positive Significance: 6/10

View Original Filing →

Current Report Filed: 2026-03-31

Key Insights

• Cocrystal Pharma announced its fiscal year 2025 results, providing an update on the company's operations and financial performance.
• The company did not provide any forward-looking guidance or details on new product development or regulatory milestones.
• Without additional information on the company's plans and pipeline, it is difficult to assess the long-term growth prospects for Cocrystal Pharma.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-02-25

Key Insights

• Phillip Frost, a 10% owner and director of Cocrystal Pharma, Inc. (COCP), purchased 20,000 shares of the company's common stock at an average price of $0.9976 per share, indicating confidence in the company's prospects.
• The shares purchased by Frost were held indirectly through Frost Gamma Investments Trust, which now holds a total of 1,908,551 shares of COCP, representing a significant ownership stake.
• Frost's insider buying activity, combined with his existing substantial ownership position, suggests he believes the company's stock is undervalued and presents an attractive investment opportunity.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-02-19

Key Insights

• Cocrystal Pharma announced the development of its first oral norovirus protease inhibitor CDI-988, which will be featured at the upcoming ICAR 2026 conference in Prague.
• The company's focus on developing a norovirus treatment indicates potential growth opportunities in the antiviral drug market.
• Investors should monitor the progress and data presented on CDI-988 at the ICAR conference for insights into the compound's development and potential future commercialization.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-09

Key Insights

• Dr. Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), acquired an additional 50,000 shares of the company's common stock on February 6, 2026 at an average price of $0.9456 per share.
• Dr. Frost's total beneficial ownership in COCP increased to 1,888,551 shares, indicating his strong conviction in the company's prospects.
• The filing also shows that Dr. Frost holds shares indirectly through Frost Gamma Investments Trust, suggesting a long-term investment strategy in the company.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-01-15

Key Insights

• Cocrystal Pharma granted stock options to its directors, executive officers, and a consultant, indicating potential alignment of interests between management and shareholders.
• The stock options have a 10-year term and vest over time, which could incentivize long-term performance and retention of key personnel.
• The company also awarded a $50,000 cash bonus to the chairman of its Scientific Advisory Board, suggesting the importance of scientific expertise to Cocrystal's business.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• Richard C. Pfenniger Jr., a director of Cocrystal Pharma, Inc. (COCP), has been granted 16,410 non-qualified stock options with a 10-year term and an exercise price of $1.10 per share.
• The options will vest in two equal tranches, with the first half vesting on January 9, 2027 and the remaining half vesting in eight equal quarterly installments starting on March 31, 2027, subject to Pfenniger's continued service as a director.
• This grant of options aligns Pfenniger's interests with those of COCP shareholders and incentivizes him to contribute to the company's long-term success.

Sentiment: Positive Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• The reporting person, Roger D. Kornberg, was granted 24,615 non-qualified stock options by Cocrystal Pharma, Inc. (COCP) on January 9, 2026, with a 10-year term and an exercise price of $1.10 per share.
• The stock options will vest in two tranches, with 50% vesting on January 9, 2027 and the remaining 50% vesting in 8 equal quarterly installments starting March 31, 2027, contingent on Kornberg's continued service as a director.
• This stock option grant suggests that Cocrystal Pharma is incentivizing and retaining its board members, which could signal confidence in the company's long-term prospects.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• Insider Sam Lee, President and Co-CEO, acquired 49,229 stock options in Cocrystal Pharma, Inc. (COCP) on January 9, 2026, potentially indicating his confidence in the company's future performance.
• The stock options granted to Lee have a 10-year term and will vest over time, aligning his interests with those of other shareholders.
• The transaction was reported on a timely basis, suggesting transparent communication with investors about insider trading activities.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• Fred Hassan, a director of Cocrystal Pharma, Inc. (COCP), was granted 16,410 non-qualified stock options on January 9, 2026, vesting over two years.
• The stock options have an exercise price of $1.1 per share and are exercisable until January 9, 2036.
• This insider grant suggests the director's confidence in the company's future prospects and alignment with shareholder interests.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• The reporting person, James Martin, has been granted 49,229 stock options with an exercise price of $1.1 and a 10-year expiration, as part of the company's 2025 Equity Incentive Plan.
• The options will vest in two tranches, with half vesting on January 9, 2027 and the remaining half vesting in eight equal quarterly installments starting March 31, 2027, subject to his continued service as an officer.
• This stock option grant suggests the company is incentivizing the Co-CEO and CFO to remain with the organization and drive long-term value creation.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• Dr. Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), was granted 24,615 non-qualified stock options on January 9, 2026 under the company's 2025 Equity Incentive Plan.
• The stock options have a 10-year term and will vest in two installments, with half vesting on January 9, 2027 and the remaining half vesting in eight equal quarterly installments starting March 31, 2027.
• Dr. Frost's ownership of COCP stock options provides alignment with other shareholders and incentivizes him to continue serving on the company's board of directors.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• Anthony J. Japour, a director of Cocrystal Pharma, Inc. (COCP), was granted 16,410 non-qualified stock options on January 9, 2026 with a 10-year expiration and exercise price of $1.1 per share.
• The stock options will vest in two tranches: 50% on January 9, 2027 and the remaining 50% in eight equal quarterly installments starting on March 31, 2027, subject to Japour's continued service as a director.
• This grant of stock options to a director is a common form of equity compensation to align the interests of the board with shareholders.

Sentiment: Positive Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-01-13

Key Insights

• The reporting person, Steven Rubin, has been granted 16,410 non-qualified stock options by Cocrystal Pharma, Inc. (COCP) under the company's 2025 Equity Incentive Plan.
• The stock options have a 10-year term and will vest in two equal installments, with half vesting on January 9, 2027 and the remaining half vesting in eight quarterly installments starting on March 31, 2027, subject to Rubin's continued service as a director.
• This stock option grant aligns the interests of the reporting person, who is a director of COCP, with those of the company and its shareholders, as it provides an incentive for Rubin to contribute to the company's long-term success.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-02

Key Insights

• Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), purchased 50,000 shares of the company's common stock on December 31, 2025 at an average price of $0.9455 per share.
• Frost Gamma Investments Trust, of which Phillip Frost is the trustee, owns a significant stake of 1,838,551 shares in COCP, indicating Frost's continued confidence in the company.
• The Form 4 filing also discloses that Frost has disposed of 27,100 shares, likely for portfolio rebalancing or liquidity purposes.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2025-12-31

Key Insights

• Phillip Frost, a 10% owner of Cocrystal Pharma, Inc. (COCP), purchased an additional 20,000 shares of common stock on December 30, 2025 at a weighted average price of $0.9655 per share.
• Frost Gamma Investments Trust, which is controlled by Phillip Frost, holds a significant indirect beneficial ownership stake of 1,788,551 shares in COCP.
• The Form 4 filing does not include any securities owned directly by OPKO Health, Inc., a company where Phillip Frost is the Chairman and CEO, as he disclaims beneficial ownership of those shares.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2025-12-29

Key Insights

• Insider Phillip Frost, MD ET AL, reported purchasing a total of 65,000 shares of Cocrystal Pharma, Inc. (COCP) on December 24 and 26, 2025, increasing his indirect beneficial ownership to 1,768,551 shares.
• The reported purchases were made at weighted average prices of $0.9703 and $0.9736 per share, suggesting Dr. Frost believes the stock is undervalued at current levels.
• The filing indicates Dr. Frost holds his COCP shares through Frost Gamma Investments Trust, of which he is the trustee, suggesting he maintains a long-term investment strategy in the company.

Sentiment: Positive Significance: 7/10

View Original Filing →